Gyre Therapeutics Inc (FRA:L9S)
€ 9.45 -0.95 (-9.13%) Market Cap: 798.92 Mil Enterprise Value: 776.74 Mil PE Ratio: 0 PB Ratio: 13.60 GF Score: 26/100

Catalyst Biosciences Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript

Jun 23, 2021 / 03:20PM GMT
Timur Ivannikov
Raymond James Financial Services, Inc. - Analyst

Hello, everyone. My name is Timur Ivannikov and I am a Biotech Analyst at Raymond James. Today, we are pleased to host senior management team of Catalyst Biosciences at our annual Human Health Innovation Conference.

Today, we are hosting Nassim Usman, President and CEO of Catalyst; Howard Levy, Chief Medical Officer; and Chief Financial Officer, Clinton Musil; and SVP Translational Research, Grant Blouse. For everyone on the line, thank you for joining us today, and feel free to submit questions virtually. Nassim, I will hand it over to you for an overview of the Company before we get into the Q&A portion.

Nassim Usman
Catalyst Biosciences, Inc. - President & CEO

Thank you, Timur, and thank you all who are attending today. So good morning. Today, I will be making forward-looking statements during the presentation and during the Q&A.

So what is Catalyst Biosciences? We are the protease medicines company. And what we do is harness the catalytic power of proteases.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot